After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA ...

Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.

Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Offi...

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar...

Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua...

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.